No Case of Coronavirus after One Million Chinese Received an Experimental Covid-19 Vaccine

0
33
Chinese Covid-19 vaccine
Image by SurasakTH from Pixabay

Nearly one million people in China have reportedly received the experimental Chinese COVID-19 vaccine which is currently in its final trials. This Chinese COVID-19 vaccine is developed by China National Pharmaceutical Group (Sinopharm). These people were given this vaccine in the month of July and include government officers, workers, housewives, students, etc.

Sinopharm’s chairman, Liu Jingzhen shared that all these participants who received this vaccine have been saved from the virus. They have traveled to many other countries and there is not a single coronavirus case after their vaccine inoculation.

Also read- Which Fabric Mask For Coronavirus Is Most Effective?

He also shared that only some of the patients have reported some mild signs. Sinopharm has 2 vaccine candidates which belong to the 5 Chinese candidates which are under numerous international trials shows that coronavirus prevalence in China is now low.

Three of these vaccines made by Sinopharm and Sinovac, both inactivated vaccines are now approved to be used in an emergency, on people who are not a part of these clinical trials. Even some of the local government bodies have allowed the local residents to try the Sinovac COVID-19 vaccine.

Earlier, the UAE was the only country that granted approval to the Sinopharm, a Chinese COVID-19 vaccine for its residents.

These international trials are somehow a part of a bigger controversy mainly because of the lack of communication with the Chinese bodies. In the month of August, Papua New Guinea banned 48 Chinese workers to enter its territory over a concern that they might be infected.

Surprisingly, some of the countries have already gone ahead in this vaccine development program without even completely the phase three trials. For example, the Chinese COVID-19 vaccine and Russian COVID-19 vaccine are available to the public but their testing is still not completed. For this reason, both these vaccines have received high criticism from a number of international health experts.

They have warned about using these incompletely tested vaccines as they have not fully complied with the international standards and testing regulations. Short cuts like these may go against the best interest of the public regarding health and safety measures and reduce the trend of taking vaccines, especially by the most vulnerable populations.

Also read- An Arthritis Medicine ‘Tocilizumab’ Can Help Treating Chronic Covid Symptoms

This Chinese COVID-19 vaccine will be sent to many countries including the Philippines and some countries on the African continent. The Chinese president urged cooperation from all international bodies and countries for developing and supplying the COVID-19 vaccine.

Nearly one dozen companies are currently in their final trials phase and we are near to get the COVID-19 vaccine. Some of the governments have already nominated their recipients while others have set up a complete supply chain process to deliver the vaccine, once it is available.

Pfizer/BioNTech has revealed their data implying that their vaccine is 90% effective. Moderna/NIH vaccine, on the other side, is in news for providing 95% protection, based on the trial results.

Dr. Anthony Fauci, a US infectious disease expert says that both these companies, Pfizer/ BioNTech and Moderna have come up with impressive results so there are high chances that the US government will grant them emergency authorization by the end of this year.

 

 

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here